COMPANY PROFILE

Switch Therapeutics

Switch Therapeutics is a biotech company dedicated to revolutionizing RNA interference (RNAi) therapies with conditionally activated siRNAs (CASi)

South San Francisco, United StatesFounded 2020Biotech & Life Sciences

Valuation $250–500M Last recorded · 2023

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Switch Therapeutics

Switch Therapeutics is an innovative biotechnology startup that is revolutionizing the field of RNAi (RNA interference) medicine. RNAi is a biological process where RNA molecules inhibit gene expression, effectively 'switching off' certain genes. This technology has the potential to treat a range of serious diseases by targeting specific cell populations based on their internal gene expression.

Founded in 2020, Switch Therapeutics is developing biomarker-gated genetic medicines, which are drugs that are activated or deactivated by biological markers in the body. This approach could transform the treatment of diseases by offering more personalized and effective therapies. The company's research is based on the work conducted at renowned institutions such as Caltech, Harvard Medical School, and City of Hope.

Switch Therapeutics operates in the biotech market, a highly competitive and rapidly evolving sector. The company's business model involves raising funds through venture capital and other financing methods to support its research and development activities. In 2022, the company raised $52 million in financing and moved into its own facility in South San Francisco.

The company's target clients are primarily patients suffering from serious diseases that could potentially be treated with RNAi medicines. These could include conditions such as AIDS-related lymphoma, pancreatic cancer, and liver cancer, among others.

In summary, Switch Therapeutics is a promising biotech startup that is leveraging cutting-edge RNAi technology to develop innovative treatments for serious diseases.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2020
Headquarters: South San Francisco, United States
Employees: 28
Open positions: None listed
Dealroom signal: 62.5/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	Mar 2023	$52M	$208M	Upfront Ventures · Bold Capital Partners · Digitalis Ventures · Freeflow Ventures	↗
SPINOUTOther financing	Jan 2020	$0	—	Caltech, California Institute of Technology	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Switch Therapeutics website traffic

Latest recorded traffic for Switch Therapeutics is 940 monthly website visits, down 27.7% over the last three months. Switch Therapeutics's team declined 9.7% over the past year.

Latest monthly visits940 3-month web change-27.7% 1-year team growth-9.7%

Monthly website visitsMar 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Senior/Principal Scientist, In Vivo Pharmacology (Oligonucleotides)South San Francisco, California, United States, Northern America, Americas · Other · Aug 27, 2026 Senior/Principal Scientist, Analytical & Bioanalytical ChemistrySouth San Francisco, California, United States, Northern America, Americas · Other · Aug 27, 2026

2 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
KTKelonia TherapeuticsDeveloping a new wave of genetic medicines using its next generation vivo gene delivery platform	Boston, United States	Acquired	65	$50M	$3.3B
TTTranscend TherapeuticsDeveloping the next generation of psychoactive compounds for neuropsychiatry focused on patient access	New York City, United States	Acquired
ATAtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance	L'Hospitalet de Llobregat, Spain	Operational
PHPhost’inA biopharmaceutical company focused on the discovery and development of N-glycosylation inhibitors	Montpellier, France	Operational
MTModalis TherapeuticsEpigenetic gene modulation therapies for genetic disorders	Cambridge, United States	Operational
ATAsgard TherapeuticsSpin-off company from Lund University focusing on developing cancer immunotherapies based on cell fate reprogramming	Lund Municipality, Sweden	Operational
AFAelis FarmaBiotech company conducting research and development on innovative signaling specific drugs	Bordeaux, France	Operational
ZIZelluna ImmunotherapyPrivately owned Norwegian biopharmaceutical company	Oslo, Norway	Acquired